Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NV;FZ|E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr6NnBKUUN3ME2wMlA3OSEQvF2= M{PaNHNCVkeHUh?=
ALL-PO MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPCc3dKSzVyPUCuNFY{PTVizszN NWnt[|FbW0GQR1XS
697 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXsTWM2OD1yLkC5PVc3KM7:TR?= NHe2c5pUSU6JRWK=
NCI-H748 NIf4cpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDUTWM2OD1yLkGwN|M1KM7:TR?= MnPEV2FPT0WU
NKM-1 NFfxVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2H5[GlEPTB;MD6xNFkyOiEQvF2= M2fYR3NCVkeHUh?=
ES1 Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLCbWpKSzVyPUCuNVEzPTVizszN MmjsV2FPT0WU
NCI-H1963 MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HHNGlEPTB;MD6xNVU4QSEQvF2= MkPLV2FPT0WU
NCI-H1417 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMUK5O|Qh|ryP MXXTRW5ITVJ?
NEC8 NEexRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjNWIJrUUN3ME2wMlE{PTJ5IN88US=> M4Tje3NCVkeHUh?=
CRO-AP2 NXTLNmx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e5SWlEPTB;MD6xOlg5QSEQvF2= MYDTRW5ITVJ?
A3-KAW NYDwO5NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\qR4JUUUN3ME2wMlE4PjJ5IN88US=> MlmwV2FPT0WU
SF539 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\SO5ZKSzVyPUCuNVk2QTNizszN MUjTRW5ITVJ?
NOS-1 NFLkbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXnTWM2OD1yLkG5OlE6KM7:TR?= NXH6VY0yW0GQR1XS
NTERA-S-cl-D1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\IR5BKSzVyPUCuNlAyOTNizszN MUfTRW5ITVJ?
COR-L88 M{\mZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTJVpZkUUN3ME2wMlIzQTV7IN88US=> NVzkVJBMW0GQR1XS
EM-2 M4W0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPZc4dyUUN3ME2wMlI1ODd7IN88US=> NVnhbIp[W0GQR1XS
KARPAS-45 Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDB[5VKSzVyPUCuNlc5OzNizszN M1TYdnNCVkeHUh?=
DSH1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jqcWlEPTB;MD6yPFcxQCEQvF2= NF\RZopUSU6JRWK=
HT-144 NIftW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwM{CyOVYh|ryP MVXTRW5ITVJ?
ATN-1 MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPlTWM2OD1yLkOwOVc3KM7:TR?= M{[wSHNCVkeHUh?=
HEL NV;uVFRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrJTmd6UUN3ME2wMlMyOzR6IN88US=> NWfyTmFvW0GQR1XS
NB12 NWjHc4FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13qTmlEPTB;MD6zNVc2PiEQvF2= NWC4Z2I3W0GQR1XS
LU-139 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwM{O1NUDPxE1? NEmz[nBUSU6JRWK=
J-RT3-T3-5 NVXWdWhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLOdph1UUN3ME2wMlM{PzF4IN88US=> MXzTRW5ITVJ?
MOLT-13 NYfOV2d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HKXmlEPTB;MD6zN|gyKM7:TR?= NUnhR3Y3W0GQR1XS
SR NX7lXXNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj5d29bUUN3ME2wMlM1OjZzIN88US=> MW\TRW5ITVJ?
CMK NUDWOoVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\zTWM2OD1yLkO1O|I4KM7:TR?= MmHOV2FPT0WU
ES8 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwM{[wNlIh|ryP NEPvV2tUSU6JRWK=
LB647-SCLC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\WOYhKSzVyPUCuN|Y4OyEQvF2= M3fSTXNCVkeHUh?=
TE-8 M4WyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHVTWM2OD1yLkO2PVM2KM7:TR?= MlLYV2FPT0WU
BV-173 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwM{exNlEh|ryP MkniV2FPT0WU
DEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\rO3h1UUN3ME2wMlM4PDh5IN88US=> MoDEV2FPT0WU
ARH-77 NH34VGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPYNFVKSzVyPUCuN|gyQTNizszN MVvTRW5ITVJ?
NCCIT M{Xy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPqWZJPUUN3ME2wMlM5PjR7IN88US=> M1vSbnNCVkeHUh?=
RPMI-8402 NIfObY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjFTmxKSzVyPUCuN|g4ODFizszN MY\TRW5ITVJ?
MONO-MAC-6 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwM{i3O|Yh|ryP MVLTRW5ITVJ?
SK-MM-2 NYjk[ZZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwM{m4Olgh|ryP MVrTRW5ITVJ?
CHP-126 NWXEUok2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j4dmlEPTB;MD60NFI{OSEQvF2= MoTKV2FPT0WU
A101D MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq3NHJKSzVyPUCuOFA{KM7:TR?= MXnTRW5ITVJ?
SCH MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfoT3lKSzVyPUCuOFA{PDJizszN MmGwV2FPT0WU
NMC-G1 NGHnfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X0[mlEPTB;MD60NFM3PyEQvF2= MWnTRW5ITVJ?
NCI-H209 NV\TdFVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[3[3l2UUN3ME2wMlQxPjF|IN88US=> M1TQRXNCVkeHUh?=
MOLT-16 NVG3SlRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C2XWlEPTB;MD60NVAyPyEQvF2= M3exNHNCVkeHUh?=
RPMI-6666 M3n5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T4bmlEPTB;MD60NVEzKM7:TR?= MoLWV2FPT0WU
OPM-2 NFW0OXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnmTWM2OD1yLkSxOVE{KM7:TR?= Mn;EV2FPT0WU
MRK-nu-1 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwNEOxOVMh|ryP NH3qRWlUSU6JRWK=
BC-1 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke2TWM2OD1yLkSzOFA{KM7:TR?= MVnTRW5ITVJ?
MHH-NB-11 MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3YTWM2OD1yLkSzOFU{KM7:TR?= MX3TRW5ITVJ?
Ramos-2G6-4C10 M2PJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrpRY9EUUN3ME2wMlQ{QDl5IN88US=> MXvTRW5ITVJ?
LS-513 NFzOWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vYZWlEPTB;MD60OFUxOSEQvF2= Mn7CV2FPT0WU
K5 NWWyUoxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPNNI5KSzVyPUCuOFcxOjVizszN NVrOd292W0GQR1XS
HOP-62 NEHm[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj0TWM2OD1yLkS4N|U5KM7:TR?= M13OSnNCVkeHUh?=
NCI-H187 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv4TWM2OD1yLkS5NlI4KM7:TR?= M37W[3NCVkeHUh?=
BE-13 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwNEm2OlEh|ryP MWPTRW5ITVJ?
HC-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnraTWM2OD1yLkWwOFc{KM7:TR?= MXPTRW5ITVJ?
ACN NXv4ZXJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwNUGwNlgh|ryP M3PLUXNCVkeHUh?=
HCC1599 M4fqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwNUG1O{DPxE1? MojUV2FPT0WU
MV-4-11 MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnvS|VKSzVyPUCuOVMxPDFizszN M{fMeHNCVkeHUh?=
LC-2-ad NF7x[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LzR2lEPTB;MD61N|Y3OyEQvF2= M1THd3NCVkeHUh?=
HL-60 NF3mcm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwNUSyOlEh|ryP MXHTRW5ITVJ?
NB17 NVL6[FNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3JTWM2OD1yLkW0N|gh|ryP MXnTRW5ITVJ?
TE-1 MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnziTWM2OD1yLkW1N|A3KM7:TR?= Mn\IV2FPT0WU
NCI-H524 NE\1[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWP5elMxUUN3ME2wMlU2PDBzIN88US=> M1K0TnNCVkeHUh?=
MZ7-mel NICySJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETkRW9KSzVyPUCuOVYyODVizszN MWDTRW5ITVJ?
L-363 M4P4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwNU[2OVch|ryP MnXTV2FPT0WU
BL-41 MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\vPGlEPTB;MD61Olg5QSEQvF2= MYfTRW5ITVJ?
LU-134-A NUjjTZNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwNUewO|Mh|ryP M4jDfnNCVkeHUh?=
SIG-M5 M{X6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHB[IE{UUN3ME2wMlU4QDR6IN88US=> NGrkcXVUSU6JRWK=
ONS-76 M{jTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfLZnVKSzVyPUCuOVgzPDJizszN M4rYXHNCVkeHUh?=
KARPAS-299 MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OwOWlEPTB;MD61PFUxPCEQvF2= NXvXXId{W0GQR1XS
DU-4475 MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy0Z3A1UUN3ME2wMlU5PzB|IN88US=> MWXTRW5ITVJ?
NB69 NF\aZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nnXmlEPTB;MD61PVgzPSEQvF2= MWHTRW5ITVJ?
MHH-PREB-1 M3vuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDLTWM2OD1yLk[wO|E6KM7:TR?= M4nEPHNCVkeHUh?=
LU-165 NUWxW2xVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W5bGlEPTB;MD62NVgyOiEQvF2= NIPyPGxUSU6JRWK=
LOUCY MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwNkOzOlQh|ryP NWe0WYRNW0GQR1XS
NCI-H526 Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwNkO1OFEh|ryP MYjTRW5ITVJ?
KE-37 M{Wycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm3TWM2OD1yLk[0Nlc3KM7:TR?= NWK1U3F5W0GQR1XS
NALM-6 MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XHN2lEPTB;MD62OFg3KM7:TR?= NV[4OIFiW0GQR1XS
CW-2 NFr5fYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LpZmlEPTB;MD62OVc6PCEQvF2= MmnaV2FPT0WU
SU-DHL-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO2[IVyUUN3ME2wMlY2QTR5IN88US=> MY\TRW5ITVJ?
NB13 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HWRWlEPTB;MD62OlgyPyEQvF2= NXi0WI9iW0GQR1XS
QIMR-WIL M3:zbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETWPIxKSzVyPUCuOlg{PDNizszN M4K4T3NCVkeHUh?=
ECC12 NIGzWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknVTWM2OD1yLkewNFg3KM7:TR?= NI[zeWZUSU6JRWK=
KALS-1 NHzkeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nkV2lEPTB;MD63NFQ6OiEQvF2= NH;yZ|RUSU6JRWK=
COR-L279 NWfnWWZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH0TWM2OD1yLkewPVk3KM7:TR?= Ml\TV2FPT0WU
NB14 M3XJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmWyTWM2OD1yLkeyOlE4KM7:TR?= M1X1cnNCVkeHUh?=
CCRF-CEM MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3T[WRXUUN3ME2wMlc1PjZzIN88US=> MYHTRW5ITVJ?
SW954 Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDOboE4UUN3ME2wMlc2QTl7IN88US=> NYfs[oFEW0GQR1XS
IST-SL1 NFHJNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Pl[WlEPTB;MD63O|M1QCEQvF2= MnnvV2FPT0WU
LAMA-84 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHiS3BKSzVyPUCuO|c2PjdizszN M13oeXNCVkeHUh?=
Daudi NHP6bGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP6RWI6UUN3ME2wMlc4PjhzIN88US=> MYPTRW5ITVJ?
BC-3 NGT6NJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwN{izNFgh|ryP M2PBOXNCVkeHUh?=
HCC2998 NG\tSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL0SIdKSzVyPUCuO|g{PiEQvF2= MmfCV2FPT0WU
NCI-H69 M1qzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rzSGlEPTB;MD64NFE1PyEQvF2= M1zuPHNCVkeHUh?=
CPC-N NIPvbGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D5OWlEPTB;MD64NFUzPCEQvF2= NEnxbJdUSU6JRWK=
NOMO-1 Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnznTWM2OD1yLkixNFg1KM7:TR?= M33BfHNCVkeHUh?=
CESS MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwOEGxPVch|ryP NHrKfVNUSU6JRWK=
LC4-1 MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwOESwNFch|ryP MXjTRW5ITVJ?
BL-70 NHLub|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwOEW3NFIh|ryP NE\qelNUSU6JRWK=
ES4 NXHmTph3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTRTWM2OD1yLki1PFY5KM7:TR?= MlfEV2FPT0WU
HCE-T MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;yTWM2OD1yLki3NVcyKM7:TR?= MlzrV2FPT0WU
JAR NGfR[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwOEe4Nlch|ryP MkLVV2FPT0WU
ST486 NX3KVmJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXBTWM2OD1yLki3PVE4KM7:TR?= NHLUUJJUSU6JRWK=
KS-1 M4P3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Cyc2lEPTB;MD64PFA6PiEQvF2= NU\iPIdvW0GQR1XS
GDM-1 NHPFSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwOEi2PFch|ryP M3WyO3NCVkeHUh?=
EHEB NYXsVnlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfRSVlKSzVyPUCuPVI2QDVizszN NUXrXFNJW0GQR1XS
LB2518-MEL NIjZbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\GTWM2OD1yLkmzNlg1KM7:TR?= MUnTRW5ITVJ?
GOTO NGj2cJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TPR2lEPTB;MD65OVA4PiEQvF2= M1LSenNCVkeHUh?=
LXF-289 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW5W4JpUUN3ME2wMlk2QTBzIN88US=> NH7Q[FJUSU6JRWK=
ES6 M1myZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPLTWM2OD1yLkm2OFM4KM7:TR?= MnPKV2FPT0WU
OS-RC-2 NW\1dZhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13RNGlEPTB;MD65Olg{KM7:TR?= NHrVcHpUSU6JRWK=
DMS-153 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLkcWZKSzVyPUCuPVc1PjlizszN M2\u[HNCVkeHUh?=
SK-PN-DW MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoiwTWM2OD1yLkm3PFMyKM7:TR?= NWLW[YI2W0GQR1XS
HH NGHIV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTM[VV6UUN3ME2wMlk5QTV7IN88US=> MU\TRW5ITVJ?
SH-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVKySHVoUUN3ME2xMlAzPDFizszN M4HsOHNCVkeHUh?=
MOLT-4 NEDTSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPKWVZKSzVyPUGuNFM1PTRizszN MkP3V2FPT0WU
TGW Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfjNXhKSzVyPUGuNFc3PzVizszN MnrrV2FPT0WU
L-540 NXHkTVJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLvTWM2OD1zLkGwOlA1KM7:TR?= M3K2bHNCVkeHUh?=
PF-382 NVm3OXhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFwMUG1NVMh|ryP NHX3eWhUSU6JRWK=
LC-1F MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUG5bXZTUUN3ME2xMlEzODB5IN88US=> MYXTRW5ITVJ?
OVCAR-4 M3PRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwMUOxOlUh|ryP M1XvdnNCVkeHUh?=
A4-Fuk NIHYe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn3S4JKSzVyPUGuNVU{PjRizszN MoLPV2FPT0WU
HCC2218 NVXL[2kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfMXpVKSzVyPUGuNVY3PDFizszN M174XnNCVkeHUh?=
HAL-01 Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjPTWM2OD1zLkG2PVQ{KM7:TR?= NXPnOJRyW0GQR1XS
IST-MEL1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfObW1mUUN3ME2xMlE4PjV7IN88US=> NFnydYFUSU6JRWK=
NCI-H719 Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL1TWM2OD1zLkG3PFk5KM7:TR?= NEHLTFhUSU6JRWK=
EVSA-T NUftPIxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDjflF3UUN3ME2xMlE5OTF2IN88US=> MnrqV2FPT0WU
SK-NEP-1 Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PCRWlEPTB;MT6yNFI3PiEQvF2= NF3m[HZUSU6JRWK=
OCUB-M MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;R[GlKSzVyPUGuNlE1QDlizszN MWrTRW5ITVJ?
MEG-01 Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LLZmlEPTB;MT6yNlEyQCEQvF2= NHXF[pFUSU6JRWK=
no-10 NUH0SJdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3ye5lKSzVyPUGuNlMyOTJizszN M{DjfXNCVkeHUh?=
MHH-CALL-2 NHjSc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnQe5pPUUN3ME2xMlI1PzJzIN88US=> MlHkV2FPT0WU
SK-N-DZ M1TxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vtWWlEPTB;MT6yOFc4PiEQvF2= NH3MUYhUSU6JRWK=
SCLC-21H NWD6T3N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTBTWM2OD1zLkK2OFc5KM7:TR?= M4\2UnNCVkeHUh?=
CTV-1 M1nhWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\IcHBKSzVyPUGuNlc1OjVizszN M{[5NXNCVkeHUh?=
NB1 M13FPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj4TWM2OD1zLkK3O|MzKM7:TR?= NIPEOXpUSU6JRWK=
NCI-H64 NYDiV5NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\HeoZSUUN3ME2xMlI5PDZ{IN88US=> NEDmSopUSU6JRWK=
MDA-MB-134-VI NE[z[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LnV2lEPTB;MT6yPFU4PyEQvF2= NUK1[GJnW0GQR1XS
LB2241-RCC MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;lfmlEPTB;MT6yPFY3OyEQvF2= NVew[ZNMW0GQR1XS
8-MG-BA NIPmeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXFW4pKSzVyPUGuNlg5PjZizszN MofrV2FPT0WU
LP-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrjb21KSzVyPUGuNlk6PDdizszN NIPWXZpUSU6JRWK=
LS-411N MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfHb3lKSzVyPUGuN|A6QThizszN M{\yWHNCVkeHUh?=
CAL-148 NWLhOnc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX6dmNoUUN3ME2xMlMzPTR{IN88US=> MUTTRW5ITVJ?
NCI-H2171 Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[wTWM2OD1zLkO0OVAzKM7:TR?= NVizbHRkW0GQR1XS
JiyoyeP-2003 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFwM{WzPUDPxE1? NFfTVo5USU6JRWK=
NCI-H2107 NILQWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDTNHRNUUN3ME2xMlM2QDh|IN88US=> M{jXcnNCVkeHUh?=
BB30-HNC NWnPfYNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL6bIVoUUN3ME2xMlM5QTd6IN88US=> MoT1V2FPT0WU
K-562 NXT0NlRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFwM{myNVkh|ryP NXHIW|RoW0GQR1XS
PSN1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFwNEKyPFch|ryP NW\IcopFW0GQR1XS
HCC2157 NG\HPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfzUHFGUUN3ME2xMlQzPjlzIN88US=> NV3SWmN7W0GQR1XS
SBC-1 NEjCNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjBPG1KSzVyPUGuOFI4PDFizszN NF7yXohUSU6JRWK=
MC116 M4LGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL0bY5nUUN3ME2xMlQ{PjF3IN88US=> NIW2XFdUSU6JRWK=
KARPAS-422 NX3RfYdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHqc5Y6UUN3ME2xMlQ2OzV6IN88US=> NXjOWVdmW0GQR1XS
LB996-RCC M3Pq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYCxNJV2UUN3ME2xMlQ4OTB|IN88US=> MWPTRW5ITVJ?
MSTO-211H MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DPeGlEPTB;MT60O|k5PyEQvF2= NFzyTlZUSU6JRWK=
BT-474 NUixT3N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDYeXhKSzVyPUGuOVE4PjRizszN M1HtNHNCVkeHUh?=
A388 NGDxe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXyTWM2OD1zLkWxPVQ2KM7:TR?= M3KzR3NCVkeHUh?=
SJSA-1 NX;Te5FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLlOVBKSzVyPUGuOVIzPiEQvF2= MUnTRW5ITVJ?
COLO-829 M2LWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFwNUO1OlQh|ryP M2DuS3NCVkeHUh?=
KM-H2 Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwNU[2O{DPxE1? M{LUU3NCVkeHUh?=
GR-ST NYfIOmNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfiNoVKSzVyPUGuOVY5OiEQvF2= Mlr4V2FPT0WU
RPMI-8866 NVzUU|NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy2fYFKSzVyPUGuOlAyPDRizszN M2rlWHNCVkeHUh?=
KG-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33SOGlEPTB;MT62NVkxOSEQvF2= MYHTRW5ITVJ?
NCI-H82 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFwNkO0NFYh|ryP NFntRpFUSU6JRWK=
LB1047-RCC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPrTWM2OD1zLk[zOFU6KM7:TR?= MYHTRW5ITVJ?
KM12 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFwNkS3JO69VQ>? MWDTRW5ITVJ?
NB5 NV\4V5hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFwNkW2O|ch|ryP Mle5V2FPT0WU
HDLM-2 M3jCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwNkiyPFEh|ryP MULTRW5ITVJ?
KU812 NXXMVlhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zyZ2lEPTB;MT62PVYxPSEQvF2= M2PrXnNCVkeHUh?=
DB MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XsRmlEPTB;MT63NFM2OyEQvF2= M3P2cXNCVkeHUh?=
HD-MY-Z M3PEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjmWnhKSzVyPUGuO|UzOzRizszN MWHTRW5ITVJ?
KURAMOCHI M2OxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TTeGlEPTB;MT63O|IxPyEQvF2= NXXhU3lZW0GQR1XS
ETK-1 NHTUWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\JTGFKUUN3ME2xMlc5QDd7IN88US=> NFzqbWRUSU6JRWK=
SK-UT-1 MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;2TWM2OD1zLke5N|g5KM7:TR?= NVvtW21SW0GQR1XS
HUTU-80 M4DyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrETWM2OD1zLke5OVA5KM7:TR?= MnSwV2FPT0WU
ES7 M{DVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\nSIF4UUN3ME2xMlgxOzB{IN88US=> M3G2eHNCVkeHUh?=
SW872 M{juTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLKTWM2OD1zLkixN|k2KM7:TR?= M3vFN3NCVkeHUh?=
TK10 MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\BfFZQUUN3ME2xMlg{OTB6IN88US=> NWn1PHJVW0GQR1XS
LB831-BLC NXq0UHJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwOEO1OlMh|ryP NFPo[HZUSU6JRWK=
TE-9 M2TST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHFb3NKSzVyPUGuPFQ1OjJizszN NXr2RplUW0GQR1XS
MLMA NVL0TmxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;WNG5KSzVyPUGuPFgzOzRizszN M3r1dHNCVkeHUh?=
D-542MG Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rSSmlEPTB;MT64PVM4OyEQvF2= NVHyWJBHW0GQR1XS
EW-16 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTobnRKSzVyPUGuPVI4OiEQvF2= MWnTRW5ITVJ?
LOXIMVI NX7ucopTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C2UGlEPTB;MT65N|I5KM7:TR?= NImzTWNUSU6JRWK=
GB-1 MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HKSmlEPTB;MT65N|g3PiEQvF2= MUDTRW5ITVJ?
IST-SL2 NGTKeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJwMECyOlIh|ryP NGHTb4xUSU6JRWK=
LAN-6 NVPsXGVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTBTJJYUUN3ME2yMlAyQTZ4IN88US=> MmLmV2FPT0WU
NCI-H510A NXjhUW0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjr[mhKSzVyPUKuNFQ2ODJizszN NEfvfVVUSU6JRWK=
NCI-H1092 MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLXeoxKSzVyPUKuNFUyOjRizszN NWfKZmFuW0GQR1XS
HT MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;YTWM2OD1{LkGwOFU1KM7:TR?= NEjlb49USU6JRWK=
RL95-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfNWVdKSzVyPUKuNVE1QDJizszN MonKV2FPT0WU
NCI-H1355 M13zS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln4TWM2OD1{LkGxO|kzKM7:TR?= NFf1dZRUSU6JRWK=
NCI-H720 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJwMU[4O|Mh|ryP M3jKVHNCVkeHUh?=
NCI-H1522 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJwMkG3NlMh|ryP NIfTe5NUSU6JRWK=
LB373-MEL-D M2\3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknpTWM2OD1{LkK2PVAzKM7:TR?= M1HP[nNCVkeHUh?=
DG-75 M{DJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLYTWM2OD1{LkK3NVQ5KM7:TR?= MknNV2FPT0WU
ML-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;DdXFKSzVyPUKuN|I5PTVizszN MVPTRW5ITVJ?
SF126 M1TmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M373XmlEPTB;Mj6zN|A6PCEQvF2= MnP4V2FPT0WU
MPP-89 M2T5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PJdGlEPTB;Mj6zN|E1PSEQvF2= M3WwfnNCVkeHUh?=
NCI-H345 MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zsR2lEPTB;Mj6zN|I4PyEQvF2= MVnTRW5ITVJ?
LS-123 MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfsTlJwUUN3ME2yMlM1QTN4IN88US=> MkPFV2FPT0WU
NB10 NVjMTGhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LN[WlEPTB;Mj60NVA6OiEQvF2= M3zlN3NCVkeHUh?=
CGTH-W-1 NHvQO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL0elJKSzVyPUKuOFIzPjdizszN MkfwV2FPT0WU
CP66-MEL MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJwNEe3O{DPxE1? NH3uRW5USU6JRWK=
L-428 NH7De4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Hx[2lEPTB;Mj60PFUzOSEQvF2= M323PHNCVkeHUh?=
DMS-79 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHmxR21KSzVyPUKuOVQyODNizszN M1Pk[nNCVkeHUh?=
NCI-H1882 M2LuRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjXdHNKSzVyPUKuOlc2PjJizszN M{n6XnNCVkeHUh?=
KGN M2\2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO2VmNJUUN3ME2yMlc3QDd4IN88US=> NHjxUHZUSU6JRWK=
EW-1 NVvoNZY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJwN{ewPFMh|ryP M4rqbXNCVkeHUh?=
U-266 M2j3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfIVJFKSzVyPUKuPFQ5OjNizszN MX;TRW5ITVJ?
COLO-320-HSR MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\DR2lEPTB;Mj64OVY1OSEQvF2= NGr6d4FUSU6JRWK=
KMOE-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfHTWM2OD1{Lki3O|EyKM7:TR?= M17jUXNCVkeHUh?=
BB49-HNC NFnGVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7zb4FKSzVyPUKuPVI1QCEQvF2= NXjNdG84W0GQR1XS
GI-1 NWq4fmMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJwOUK5OVch|ryP NFzwTW1USU6JRWK=
NCI-H1304 NXfWOGlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTNwMEC1NVEh|ryP MVfTRW5ITVJ?
NCI-H2227 NH3FSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT1TWM2OD1|LkCyNFc6KM7:TR?= MnnjV2FPT0WU
U-87-MG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;tbGlKSzVyPUOuNFM2OTNizszN MXXTRW5ITVJ?
NCI-H747 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Kw[2lEPTB;Mz6wOVIxPiEQvF2= MlzxV2FPT0WU
CTB-1 NE\MfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\UPGlEPTB;Mz6wOVM4PiEQvF2= M1nnOHNCVkeHUh?=
RPMI-8226 M2nxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzlWpFKSzVyPUOuNVQ{PzhizszN M3\yOHNCVkeHUh?=
NCI-H2141 NF2xU5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i5XWlEPTB;Mz6xOlU3PiEQvF2= MYPTRW5ITVJ?
IST-MES1 NEfsO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3GNIdKSzVyPUOuNVgzPzlizszN NWr0TpVKW0GQR1XS
TE-5 Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTNwMkGzOFIh|ryP M2j3fXNCVkeHUh?=
UACC-257 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXyTWM2OD1|LkSzOlU6KM7:TR?= NVzvc2JQW0GQR1XS
SK-N-FI MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\uN4s4UUN3ME2zMlQ2OjJ5IN88US=> NE\0XohUSU6JRWK=
MFH-ino M1ew[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7PTWM2OD1|LkS2OVg6KM7:TR?= MXfTRW5ITVJ?
SF268 NFf4RYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvFTWM2OD1|LkS4NVc1KM7:TR?= MWrTRW5ITVJ?
TE-12 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTNwNUG2PVkh|ryP MV3TRW5ITVJ?
NB6 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPRTWM2OD1|LkW1OVY{KM7:TR?= Mm[3V2FPT0WU
DJM-1 NUjjRpkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\ybmlEPTB;Mz61PVg6QSEQvF2= NWnUWndtW0GQR1XS
MZ1-PC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTNwNkG2NlQh|ryP NH3CPI5USU6JRWK=
OCI-AML2 MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTNwNkK2O|Eh|ryP NGfU[2FUSU6JRWK=
NCI-H1155 M2HjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTNwN{C5OFch|ryP NE\kS|hUSU6JRWK=
RKO NFPoe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTNwN{exPFkh|ryP NVGxVmFjW0GQR1XS
ECC4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;rZ|RKSzVyPUOuPVcyQTVizszN MYLTRW5ITVJ?
BB65-RCC M4TmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrRTWM2OD1|Lkm3OVQ4KM7:TR?= MlLyV2FPT0WU
EB-3 MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn4d4x4UUN3ME2zMlk6PjN|IN88US=> NEC2c|NUSU6JRWK=
SHP-77 MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTRwMEC1NlQh|ryP M1fQS3NCVkeHUh?=
NCI-H2196 MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjjTWM2OD12LkC1OlI2KM7:TR?= MonFV2FPT0WU
GI-ME-N M{iyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[3cJh2UUN3ME20MlA3Ozl7IN88US=> NEHKZm9USU6JRWK=
MN-60 M2DBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLEW2hCUUN3ME20MlExQDdizszN NHHiTHBUSU6JRWK=
NCI-H1694 MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTRwMUO0NFUh|ryP NUXMeYo5W0GQR1XS
LU-65 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XlV2lEPTB;ND6xOVM{OiEQvF2= MWDTRW5ITVJ?
NCI-H1436 NWLhZXF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO1TWM2OD12LkG4N|M{KM7:TR?= NVL6[mxTW0GQR1XS
KINGS-1 M4HNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT4TWM2OD12LkOxOFMzKM7:TR?= M{Hle3NCVkeHUh?=
GT3TKB MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK3TWM2OD12LkOzNlY5KM7:TR?= MV;TRW5ITVJ?
Becker NUfxbpVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLKPW1KSzVyPUSuN|c{OTJizszN NXXjOIdkW0GQR1XS
HCC1187 NF;lU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTRwOEm2OVch|ryP MnrFV2FPT0WU
D-502MG MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS1TWM2OD13LkCwOFE3KM7:TR?= Mn;4V2FPT0WU
VA-ES-BJ NGLTWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTVwMUO3O|gh|ryP NVPFNm5UW0GQR1XS
NB7 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe2Z2MzUUN3ME21MlE1OTF{IN88US=> NIjMN2tUSU6JRWK=
SW962 MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[wTWM2OD13LkO4PFE1KM7:TR?= NV3uWGp2W0GQR1XS
no-11 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrBUodKSzVyPUWuO|Y{PDNizszN NV\XVXlnW0GQR1XS
KNS-81-FD NFfCbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL2VWVFUUN3ME21MlkxPjl2IN88US=> M1z3OnNCVkeHUh?=
COLO-684 MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rEPGlEPTB;NT65PVQ6PCEQvF2= NVHReYpmW0GQR1XS
D-263MG MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPvTWM2OD14LkC4PFk2KM7:TR?= MWrTRW5ITVJ?
EW-24 MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfnTWM2OD14LkK4OVEh|ryP MmfEV2FPT0WU
TE-10 MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\JfmtSUUN3ME22MlQzPjJ|IN88US=> MXXTRW5ITVJ?
EKVX MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nreGlEPTB;Nj60OlMzOSEQvF2= NVe1PXczW0GQR1XS
NCI-H1648 M4ezeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFq2NHFKSzVyPU[uOlc2PTdizszN NWnlNoN3W0GQR1XS
LB771-HNC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLPVG5IUUN3ME22MlkzOzBzIN88US=> MorSV2FPT0WU
SK-MEL-1 M4X2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRThwMUOxOlYh|ryP MULTRW5ITVJ?
COLO-668 NFvoSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLRTWM2OD16LkK3O|g3KM7:TR?= NYHBSXpvW0GQR1XS
EW-12 M1nmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRThwNEC4NFMh|ryP MojTV2FPT0WU
A253 M3rtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi5d5B[UUN3ME24Mlg1PjZzIN88US=> NGnNT5RUSU6JRWK=
NCI-H2126 NV30W4lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XYU2lEPTB;OD64PVMyQSEQvF2= NIDVV4JUSU6JRWK=
Calu-6 M2joOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7oRpI2UUN3ME24Mlk6ODR{IN88US=> MkHQV2FPT0WU
NCI-H23 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u4RmlEPTB;OT6xO|c1PiEQvF2= M2\JTnNCVkeHUh?=
WSU-NHL M2j5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnKTWM2OD17Lke3OFc5KM7:TR?= NIfv[WlUSU6JRWK=
MMAC-SF M1q1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTITWM2OD17Lkm3PVA1KM7:TR?= M1vYUHNCVkeHUh?=
SK-LMS-1 Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzGcJBKSzVyPUGwMlI5OzRizszN MVnTRW5ITVJ?
GCIY NGnQXWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnrTWM2OD1zMD61PVI1KM7:TR?= NIG0fY9USU6JRWK=
TE-15 NV6zV4Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn0e|RCUUN3ME2xNU43ODB2IN88US=> MkXwV2FPT0WU
EoL-1-cell MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jOc2lEPTB;MUGuO|Y5OiEQvF2= NGDsN2NUSU6JRWK=
NCI-H2081 M2P6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWSzbGR6UUN3ME2xNU44Pzh4IN88US=> Ml7wV2FPT0WU
EW-3 M323Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHGcVlKSzVyPUGyMlI1PjNizszN M1TCO3NCVkeHUh?=
CAS-1 M1;OfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF{LkO2N|Eh|ryP MkPCV2FPT0WU
C2BBe1 M3PHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXTZ5BUUUN3ME2xNk43OTNzIN88US=> MlzFV2FPT0WU
D-247MG MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF{Lke5OVIh|ryP Mnu0V2FPT0WU
NCI-SNU-5 NH[0R5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrGc25JUUN3ME2xNk45ODF|IN88US=> NXPRTHZKW0GQR1XS
LS-1034 M4PIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPvdox7UUN3ME2xOE4{QTd3IN88US=> MUHTRW5ITVJ?
EW-18 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF2LkS0PEDPxE1? NULzdHNnW0GQR1XS
Raji MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF2LkWwOFkh|ryP MknmV2FPT0WU
D-283MED MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF2Lk[yO|Eh|ryP NUDsbmgzW0GQR1XS
MZ2-MEL NEDSRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL6XlZEUUN3ME2xOE46Pjl4IN88US=> MVrTRW5ITVJ?
NCI-SNU-16 M3nJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTk[Y5kUUN3ME2xOU41PjN|IN88US=> NUDpbWRlW0GQR1XS
P30-OHK MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPGdIJqUUN3ME2xO{44QDNzIN88US=> NE\TeHBUSU6JRWK=
RXF393 Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn2wTWM2OD1zOT6wNVg3KM7:TR?= NX;PNmp3W0GQR1XS
NCI-H1395 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Hib2lEPTB;MkCuOlcxOyEQvF2= Mk\OV2FPT0WU
U-698-M NHTtb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq1TWM2OD1{MD63NFc2KM7:TR?= NXfZNW1MW0GQR1XS
NCI-SNU-1 NXPPWZJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7VTWM2OD1{MD63NlI{KM7:TR?= M{TES3NCVkeHUh?=
SW684 MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJzLkG3NVYh|ryP NXrmOmZKW0GQR1XS
NCI-H716 NUPUcGFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzDTWM2OD1{MT6zNVU1KM7:TR?= NE\X[FRUSU6JRWK=
JVM-2 NEXGWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJzLkSxN|Mh|ryP MnP2V2FPT0WU
NCI-H1581 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWxXWJKSzVyPUKyMlQyPDhizszN MU\TRW5ITVJ?
CA46 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rUb2lEPTB;M{GuOlk{PiEQvF2= M{\COnNCVkeHUh?=
SNB75 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLENGRKSzVyPUOzMlY2ODNizszN MnjRV2FPT0WU
KNS-42 M3XIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe5dow4UUN3ME2zOU46PjJ2IN88US=> NHzEdohUSU6JRWK=
TUR NFW0XJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfjblJUUUN3ME2zOk4xPTJzIN88US=> Mm\sV2FPT0WU
REH M3nyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uzdGlEPTB;M{euPFIyOSEQvF2= NVHmNmlJW0GQR1XS
EW-22 M3;vR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTR{LkK4PFUh|ryP M3n2N3NCVkeHUh?=
NCI-H446 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIWxcVlKSzVyPUSyMlc5PTNizszN NXHLXo1lW0GQR1XS
ES3 MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fLWWlEPTB;NEOuNVM{QSEQvF2= M3m4Z3NCVkeHUh?=
EW-11 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jYWGlEPTB;NESuPFIyQCEQvF2= MUfTRW5ITVJ?
RH-1 Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTR5LkW4NVIh|ryP MWDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03018249 Not yet recruiting Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma National Cancer Institute (NCI) August 2017 Phase 2
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals March 2017 Phase 2
NCT02936752 Not yet recruiting Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) March 2017 Phase 1
NCT03024437 Not yet recruiting Metastatic Cancer|Renal Cancer Roberto Pili|Indiana University January 2017 Phase 1|Phase 2
NCT02780804 Recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) December 2016 Phase 1
NCT02922933 Recruiting Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers Syndax Pharmaceuticals November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID